Skip to main content

Advertisement

SpringerLink
Log in

Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis

  • Biomarkers
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Treatment recommendations of early rheumatoid arthritis (RA) suggest differential management of patients on the basis of prognostic factors. In this study we aimed to investigate the relationship between autoantibodies against a novel citrullinated fibrinogen peptide (anti-CFP), smoking status, clinical activity and therapeutic response in Cuban patients with early RA, receiving treatment with methotrexate in comparison to rheumatoid factor (RF), anti-cyclic citrullinated peptide of second generation (anti-CCP2) and anti-mutated citrullinated vimentin (anti-MCV). A 6-month prospective observational study was performed in 60 early RA patients at baseline and 6 months after receiving methotrexate. Baseline and outcome measures included disease activity score of 28 joints (DAS 28), simplified disease activity index (SDAI), anti-CFP antibodies, RF, anti-CCP2 and anti-MCV. Therapeutic response was determined using 20/50/70 American College of Rheumatology (ACR) response rates. DAS28 (p < 0.0001), SDAI (p < 0.0001) as well as titres of anti-CFP (p = 0.0481), anti-CCP2 (p = 0.0082), RF IgM (p = 0.0187) and RF IgA (p = 0.0252) decreased under therapy. Multivariate analyses showed association of final anti-CFP values with sex and smoking status (p = 0.0296). It is of note that anti-CFP antibodies were one of predictors for DAS 28 (p = 0.0072) SDAI (p < 0.0001) and ACR response (p = 0.0003) in multivariate models. Anti-CFP antibodies decrease in correspondence with clinical improvement after 6-month therapy and are associated with sex and smoking status. Moreover, baseline anti-CFP antibodies, using in combination with sex, smoking status and autoantibodies (anti-CCP2, anti-MCV or RF) seems to have clinical relevance for predicting clinical activity and therapeutic response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Abbas AK, Lichtman A, Pillai S (2015) Immunología Celular y molecular, 8thva edn. Elseiver Saunders, Barcelona

    Google Scholar 

  2. Firestein GS, McInnes IB (2017) Immunopathogenesis of rheumatoid arthritis. Immunity 46:183–196. https://doi.org/10.1016/j.immuni.2017.02.006

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC et al (2016) 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol 68:1–26. https://doi.org/10.1002/art.39480

    Article  PubMed  Google Scholar 

  4. Brown PM, Pratt AG, Isaacs JD (2016) Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol 12:731–742. https://doi.org/10.1038/nrrheum.2016.175

    Article  CAS  PubMed  Google Scholar 

  5. Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. https://doi.org/10.1136/annrheumdis-2016-210715

    Article  PubMed  Google Scholar 

  6. Gonzalez-Lopez L, Rocha-Muñoz AD, Ponce-Guarneros M, Flores-Chavez A, Salazar-Paramo M, Nava A et al (2014) Anti-cyclic citrullinated peptide (anti-CCP) and anti-mutated citrullinated vimentin (anti-MCV) relation with extra-articular manifestations in rheumatoid arthritis. J Immunol Res. https://doi.org/10.1155/2014/536050

    Article  PubMed  PubMed Central  Google Scholar 

  7. Koga T, Okada A, Fukuda T, Hidaka T, Ishii T, Ueki Y et al (2017) Anti-citrullinated peptide antibodies are the strongest predictor of clinically relevant radiographic progression in rheumatoid arthritis patients achieving remission or low disease activity: a post hoc analysis of a nationwide cohort in Japan. PLoS ONE. https://doi.org/10.1371/journal.pone.0175281

    Article  PubMed  PubMed Central  Google Scholar 

  8. Aletaha D, Bluml S (2016) Therapeutic implications of autoantibodies in rheumatoid arthritis. RMD Open. https://doi.org/10.1136/rmdopen-2014-000009

    Article  PubMed  PubMed Central  Google Scholar 

  9. Kochi M, Kohagura K, Shiohira Y, Iseki K, Ohya Y (2016) Inflammation as a risk of developing chronic kidney disease in rheumatoid arthritis. PLoS ONE. https://doi.org/10.1371/journal.pone.0160225

    Article  PubMed  PubMed Central  Google Scholar 

  10. Markusse IM, de Vries-Bouwstra JK, Han KH, van der Lubbe PA, Schouffoer AA, Kerstens PJ et al (2014) Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis. Arthritis Res Ther. https://doi.org/10.1186/s13075-014-0430-3

    Article  PubMed  PubMed Central  Google Scholar 

  11. Bellucci E, Terenzi R, La Paglia S, Gentileschi A, Tripoli C, Tani C et al (2016) One year in review 2016: pathogenesis of rheumatoid arthritis. Clin Exp Rheumatol 34:793–801

    PubMed  Google Scholar 

  12. Chan ES, Cronstein BN (2010) Methotrexate-how does it really work? Nat Rev Rheumatol 6:175–178. https://doi.org/10.1038/nrrheum.2010.5

    Article  CAS  PubMed  Google Scholar 

  13. Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI (2014) Smoking and rheumatoid arthritis. Int J Mol Sci 15:22279–22295. https://doi.org/10.3390/ijms151222279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM (2017) Genetic and environmental risk factors for rheumatoid arthritis. Best Pract Res Clin Rheumatol 31:3–18. https://doi.org/10.1016/j.berh.2017.08.003

    Article  PubMed  PubMed Central  Google Scholar 

  15. Van Steendam K, Tilleman K, Deforce D (2011) The relevance of citrullinated vimentin in the production of antibodies against citrullinated proteins and the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 50:830–837. https://doi.org/10.1093/rheumatology/keq419

    Article  CAS  Google Scholar 

  16. Martínez G, Gómez JA, Bang H, Martinez L, Roggenbuck D, Burmester G et al (2016) Carbamylated vimentin represents a relevant autoantigen in Latin American (Cuban) rheumatoid arthritis patients. Rheumatol Int 36(6):781–791. https://doi.org/10.1007/s00296-016-3472-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Martínez G, Torres B, Gómez JA, Pérez H, Rodríguez AM, Portal Miranda JÁ (2018) Diagnostic value of anti-fibrinogen citrullinated peptide in rheumatoid arthritis. Reumatol Clin. https://doi.org/10.1016/j.reuma.2018.11.006

    Article  PubMed  Google Scholar 

  18. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580–1588. https://doi.org/10.1136/ard.2010.138461

    Article  PubMed  Google Scholar 

  19. Prevoo MLL, Van’t Hof MA, Kuper HH, van Leeuwen MA, van de Putte BA, van Riel PLCM (1995) Modified disease activity scores that include twentyeight-joint counts. Arthritis Rheum 38:44–48

    Article  CAS  PubMed  Google Scholar 

  20. Aletaha D, Smolen J (2005) The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 23:S100–S108

    CAS  PubMed  Google Scholar 

  21. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C et al (1995) American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:727–735

    Article  CAS  PubMed  Google Scholar 

  22. Fox DA (2016) Etiology of rheumatoid arthritis: a historical and evidence-based perspective. In: Chung KC (ed) Clinical management of the rheumatoid hand, wrist, and elbow. Springer International Publishing, Suiza, pp 13–19

    Chapter  Google Scholar 

  23. Ferraccioli G, Tolusso B, Fedele AL, Gremese E (2016) Do we need to apply a T2T strategy even in ACPA-negative early rheumatoid arthritis? YES. RMD Open. https://doi.org/10.1136/rmdopen-2016-000263

    Article  PubMed  PubMed Central  Google Scholar 

  24. Bello A, Perkins E, Jay R, Efthimiou P (2017) Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis. Open Access Rheumatol 9:67–79. https://doi.org/10.2147/OARRR.S131668

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Świerkot J, Szmyrka-Kaczmarek M, Korman L, Sokolik R, Wiland P (2012) Effect of methotrexate on serum levels of anti-CCP antibodies and different classes of rheumatoid factors in rheumatoid arthritis patients. Cent Eur J Immunol 37:253–257. https://doi.org/10.5114/ceji.2012.30802

    Article  CAS  Google Scholar 

  26. Janssen KMJ, Westra J, Chalan P, Boots AMH, De Smit MJ, Van Winkelhoff AJ et al (2016) Regulatory CD4+ T-cell subsets and anti-citrullinated protein antibody repertoire: potential biomarkers for arthritis development in seropositive arthralgia patients? PLoS ONE. https://doi.org/10.1371/journal.pone.0162101

    Article  PubMed  PubMed Central  Google Scholar 

  27. Hensvold AH, Joshua V, Li W, Larkin M, Qureshi F, Israelsson L et al (2015) Serum RANKL levels associate with anti-citrullinated protein antibodies in early untreated rheumatoid arthritis and are modulated following methotrexate. Arthritis Res Ther 17(1):239–249. https://doi.org/10.1186/s13075-015-0760-9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Verheul MK, Fearon U, Trouw LA, Veale DJ (2015) Biomarkers for rheumatoid and psoriatic arthritis. Clin Immunol 161(1):2–10. https://doi.org/10.1016/j.clim.2015.04.005

    Article  CAS  PubMed  Google Scholar 

  29. Blachère NE, Parveen S, Fak J, Frank MO, Orange DE (2015) Inflammatory but not apoptotic death of granulocytes citrullinates fibrinogen. Arthritis Res Ther 17:369–376. https://doi.org/10.1186/s13075-015-0890-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Badillo MA, Rodríguez M, Pérez MA, Daza L, Bollain JJ, Carrillo MA et al (2016) Potential protein targets of the peptidylarginine deiminase 2 and peptidylarginine deiminase 4 enzymes in rheumatoid synovial tissue and its possible meaning. Eur J Rheumatol 3:44–49. https://doi.org/10.5152/eurjrheum.2015.0055

    Article  Google Scholar 

  31. Joshua V, Schobers L, Titcombe PJ, Israelsson L, Rönnelid J, Hansson M et al (2016) Antibody responses to de novo identified citrullinated fibrinogen peptides in rheumatoid arthritis and visualization of the corresponding B cells. Arthritis Res Ther 18:284–293. https://doi.org/10.1186/s13075-016-1181-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Musaelyan A, Lapin S, Nazarov V, Tkachenko O, Gilburd B, Mazing A et al (2018) Vimentin as antigenic target in autoimmunity: a comprehensive review. Autoimmun Rev 17:926–934. https://doi.org/10.1016/j.autrev.2018.04.004

    Article  CAS  PubMed  Google Scholar 

  33. Ishigooka N, Fujii T, Abe H, Ki M, Nakashima R, Hashimoto M et al (2019) Predicting factors for disappearance of anti-mutated citrullinated vimentin antibodies in sera of patients with rheumatoid arthritis. Mod Rheumatol. https://doi.org/10.1080/14397595.2019.1621439

    Article  PubMed  Google Scholar 

  34. Cronstein BN, Aune TM (2020) Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol 16:145–154. https://doi.org/10.1038/s41584-020-0373-9

    Article  CAS  PubMed  Google Scholar 

  35. Cronstein BN, Sitkovsky M (2017) Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases. Nat Rev Rheumatol 13:41–51. https://doi.org/10.1038/nrrheum.2016.178

    Article  CAS  PubMed  Google Scholar 

  36. Khandpur R, Carmona-Rivera C, Vivekanandan-Giri A, Gizinski A, Yalavarthi S, Knight JS et al (2013) NETs are a source of citrullinated autoantigens and stimulate inflammatory responses in rheumatoid arthritis. Sci Transl Med. https://doi.org/10.1126/scitranslmed.3005580

    Article  PubMed  PubMed Central  Google Scholar 

  37. Degboé Y, Constantin A, Nigon D, Tobon G, Cornillet M, Schaeverbeke T et al (2015) Predictive value of autoantibodies from anti-CCP2, anti-MCV and anti-human citrullinated fibrinogen tests, in early rheumatoid arthritis patients with rapid radiographic progression at 1 year: results from the ESPOIR cohort. RMD Open 1:1–8. https://doi.org/10.1136/rmdopen-2015-000180

    Article  Google Scholar 

  38. Gómara MJ, Rodríguez J, Bleda MJ, Salvador JP, Sanmartí R, Haro I (2018) Comparative study of the diagnostic and prognostic value of antibodies against chimeric citrullinated synthetic peptides and CCP3/CCP3.1 assays. Clin Chem Lab Med 56:285–293. https://doi.org/10.1515/cclm-2017-0264

    Article  CAS  PubMed  Google Scholar 

  39. Edwards CJ, Kiely P, Arthanari S, Kiri S, Mount J, Barry J et al (2019) Predicting disease progression and poor outcomes in patients with moderately active rheumatoid arthritis: a systematic review. Rheumatol Adv Pract. https://doi.org/10.1093/rap/rkz002

    Article  PubMed  PubMed Central  Google Scholar 

  40. Brito Rocha S, Baldo DC, Andrade LEC (2019) Clinical and pathophysiologic relevance of autoantibodies in rheumatoid arthritis. Adv Rheumatol. https://doi.org/10.1186/s42358-018-0042-8

    Article  PubMed  Google Scholar 

  41. Muñoz-Fernández S, Otón-Sánchez T, Carmona L, Calvo-Alén J, Escudero A, Narváez J et al (2018) Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. Rheumatol Int 38:2289–2296. https://doi.org/10.1007/s00296-018-4152-8

    Article  PubMed  Google Scholar 

  42. Sivas F, Yurdakul FG, Kiliçarslan A, Duran S, Başkan B, Bodur H (2017) Relationship between smoking and structural damage, autoimmune antibodies, and disability in rheumatoid arthritis patients. Arch Rheumatol 33:45–51. https://doi.org/10.5606/ArchRheumatol.2018.6332

    Article  PubMed  PubMed Central  Google Scholar 

  43. Acosta-Mérida Á, Naranjo A, Rodríguez-Lozano C (2018) Prognostic factors for sustained remission in a "real life" cohort of rheumatoid arthritis patients. Reumatol Clin. https://doi.org/10.1016/j.reuma.2018.10.002

    Article  PubMed  Google Scholar 

  44. Bird P, Nicholls D, Barrett R, De Jager J, Griffiths H, Roberts L et al (2017) Longitudinal study of clinical prognostic factors in patients with early rheumatoid arthritis: the PREDICT study. Int J Rheum Dis 20:460–468. https://doi.org/10.1111/1756-185X.13036

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all co-workers from Rheumatology Center, Havana Cuba and Center of Genetic Engineering and Biotechnology, Havana, Cuba.

Funding

Funding was provided by National Center of Medical Genetic. Ministry of Health (Grant no. 13-99-001).

Author information

Authors and Affiliations

  1. Immunology Laboratory, National Center of Medical Genetic, Havana, Cuba

    Goitybell Martínez, Maité Martiatu & Bárbara Torres

  2. Department for Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany

    Eugen Feist

  3. Helios Clinic for Rheumatology, Vogelsang-Gommern, Germany

    Eugen Feist

  4. Center of Genetic Engineering and Biotechnology, Havana, Cuba

    Hilda Garay

Authors
  1. Goitybell Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eugen Feist
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maité Martiatu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hilda Garay
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Bárbara Torres
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

GM contributed to the study conception, data collection and interpretation, first draft of the manuscript and revision of the final manuscript. EF contributed to the study conception, final interpretation of data and revision of the final manuscript. BT contributed to the study conception, final interpretation of data and revision of the final manuscript. MM contributed to material preparation, data collection, and revision of the final manuscript. HG contributed to the study conception, material preparation, data collection and revision of the final manuscript. All approved the final manuscript.

Corresponding author

Correspondence to Goitybell Martínez.

Ethics declarations

Conflict of interest

Authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Martínez, G., Feist, E., Martiatu, M. et al. Autoantibodies against a novel citrullinated fibrinogen peptide related to smoking status, disease activity and therapeutic response to methotrexate in cuban patients with early rheumatoid arthritis. Rheumatol Int 40, 1873–1881 (2020). https://doi.org/10.1007/s00296-020-04580-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-020-04580-x

Keywords

Search

Navigation